Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4076
Sky Harbour Group
SKYH
$368M
| $298K | ﹤0.01% |
33,262
+2,785
| +9% | +$26.6K |
2024 Q2
6 quarters
|
|
4077
Hurco Companies Inc
HURC
$144M
| $298K | ﹤0.01% |
19,281
+323
| +2% | +$5.35K |
2016 Q1
39 quarters
|
|
4078
LifeVantage
LFVN
$76.4M
| $297K | ﹤0.01% |
48,251
+12,883
| +36% | +$95.4K |
2018 Q3
29 quarters
|
|
|
CMDB
4079
Costamare Bulkers Holdings
CMDB
$544M
| $297K | ﹤0.01% |
19,277
+1,453
| +8% | +$21K |
2025 Q2
2 quarters
|
|
4080
Immersion
IMMR
$245M
| $297K | ﹤0.01% |
43,679
-4,268
| -9% | -$29K |
2023 Q1
11 quarters
|
|
4081
Quantum-Si Incorporated
QSI
$339M
| $296K | ﹤0.01% |
269,415
+48,205
| +22% | +$78.5K |
2022 Q1
15 quarters
|
|
4082
Immatics
IMTX
$1.16B
| $296K | ﹤0.01% |
28,185
+2,874
| +11% | +$29K |
2023 Q1
11 quarters
|
|
4083
Virginia National Bankshares
VABK
$255M
| $295K | ﹤0.01% |
7,415
+710
| +11% | +$28.4K |
2023 Q2
10 quarters
|
|
4084
Kingstone Companies
KINS
$268M
| $295K | ﹤0.01% |
17,531
+1,484
| +9% | +$22.6K |
2025 Q2
2 quarters
|
|
4085
Rimini Street
RMNI
$396M
| $294K | ﹤0.01% |
75,893
+7,271
| +11% | +$30.2K |
2019 Q1
27 quarters
|
|
4086
Ohio Valley Banc Corp
OVBC
$210M
| $294K | ﹤0.01% |
7,364
+1,983
| +37% | +$74.7K |
2025 Q2
2 quarters
|
|
4087
Weyco Group
WEYS
$486M
| $294K | ﹤0.01% |
9,615
+869
| +10% | +$26.6K |
2022 Q2
14 quarters
|
|
4088
Protara Therapeutics
TARA
$160M
| $293K | ﹤0.01% |
55,057
+9,537
| +21% | +$53K |
2024 Q4
4 quarters
|
|
4089
Relmada Therapeutics
RLMD
$384M
| $290K | ﹤0.01% |
60,000
+50,000
| +500% | +$168K |
2025 Q2
2 quarters
|
|
4090
Core Molding Technologies
CMT
$204M
| $290K | ﹤0.01% |
14,448
+695
| +5% | +$13.3K |
2023 Q1
11 quarters
|
|
4091
CALL
Illumina
ILMN
$41.2B
| $289K | ﹤0.01% |
2,200
| – | – |
2025 Q1
3 quarters
|
|
4092
Lantronix
LTRX
$337M
| $288K | ﹤0.01% |
49,069
+37,634
| +329% | +$196K |
2023 Q3
9 quarters
|
|
|
DAWN
4093
CALL
DELISTED
Day One Biopharmaceuticals
DAWN
| $287K | ﹤0.01% |
+30,800
| New | +$257K |
2025 Q4
0 quarters
|
|
4094
iShares MSCI Taiwan ETF
EWT
$12.7B
| $285K | ﹤0.01% |
4,479
-12,121
| -73% | -$780K |
2024 Q4
4 quarters
|
|
|
GLIBA
4095
Liberty Capital Corp Series A GCI Group Common Stock
GLIBA
$924M
| $284K | ﹤0.01% |
7,704
+7,661
| +17,816% | +$269K |
2025 Q3
1 quarter
|
|
4096
MediWound
MDWD
$175M
| $282K | ﹤0.01% |
15,276
+3,747
| +33% | +$68.5K |
2024 Q2
6 quarters
|
|
4097
Quad
QUAD
$485M
| $282K | ﹤0.01% |
44,971
+4,265
| +10% | +$25.1K |
2016 Q1
39 quarters
|
|
4098
Fennec Pharmaceuticals
FENC
$358M
| $282K | ﹤0.01% |
36,597
+3,559
| +11% | +$29.2K |
2022 Q4
12 quarters
|
|
4099
iQIYI
IQ
$957M
| $281K | ﹤0.01% |
146,552
+61,825
| +73% | +$132K |
2018 Q2
30 quarters
|
|
4100
CALL
Quantum Computing Inc
QUBT
$1.85B
| $281K | ﹤0.01% |
+27,400
| New | +$390K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.